SCHEMBL1790000

SCHEMBL1790000

COC(=O)c1ccc(C2CCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
MAPT P10636 1/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
HDAC1 Q13547 1/20 0.59
HAO1 Q9UJM8 1/20 0.55
NPC1 O15118 2/20 0.55
EPHX2 P34913 1/20 0.55
HDAC3 O15379 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
DEGS1 O15121 1/20 0.53
CYP2C19 P33261 2/20 0.52
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM4E B2RXH2 2/20 0.51
GAA P10253 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944396 1.00 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL2949436 1.00 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL16684739 0.98 HDAC8 (0.61) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL15214831 0.95 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL12488363 0.95 HDAC1 (0.56) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL22453473 0.92 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL2354500 0.92 HAO1 (0.64) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL21656950 0.92 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL21656481 0.92 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6
SCHEMBL7330029 0.92 HDAC8 (0.59) ALDH1A1SMN1; SMN2MAPTHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119569569-A 1-Vinyl cyclobutene derivative and synthetic method and application thereof 南宁师范大学 2025-03-07 CN disclosed
EP-4276533-A1 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2023-11-15 EP disclosed
EP-4276534-A1 MASK BLANK, RESIST PATTERN FORMING PROCESS AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION Shin-Etsu Chemical Co., Ltd. (JP) 2023-11-15 EP disclosed
EP-3063154-B1 CROSS-COUPLING OF UNACTIVATED SECONDARY BORONIC ACIDS UNIV ILLINOIS (US) 2023-08-30 EP disclosed
EP-3063154-B1 CROSS-COUPLING OF UNACTIVATED SECONDARY BORONIC ACIDS UNIV ILLINOIS (US) 2023-08-30 EP disclosed
CN-115160098-B Oxygen-containing compound deoxidization methylation method 中国科学院兰州化学物理研究所 2023-06-06 CN disclosed
CN-115160098-A Oxygen-containing compound deoxidation and methylation method 中国科学院兰州化学物理研究所 2022-10-11 CN disclosed
US-10954258-B2 STAT3 dimerization inhibitors H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2021-03-23 US disclosed
US-10954258-B2 STAT3 dimerization inhibitors H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2021-03-23 US disclosed
US-20200199160-A1 STAT3 DIMERIZATION INHIBITORS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2020-06-25 US disclosed
EP-2249426-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY Mitsubishi Chemical Corporation (JP) 2010-11-10 EP disclosed
EP-0934276-B1 ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS XENOVA LTD (GB) 2003-12-17 EP disclosed
US-20030119816-A1 Flavone derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2003-06-26 US disclosed
US-6232290-B1 FUNGICIDES AGAINST PNEUMOCYSTIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-15 US disclosed
US-6218393-B1 IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG XENOVA LIMITED (GB) 2001-04-17 US disclosed
EP-1053247-A1 ANTIFUNGAL CYCLOHEXAPEPTIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-11-22 EP disclosed
WO-1999040108-A1 NEW COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-08-12 WO disclosed
EP-0934276-A1 ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS XENOVA LIMITED (GB) 1999-08-11 EP disclosed
WO-1998017648-A1 ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS XENOVA LIMITED (GB) 1998-04-30 WO disclosed
US-4021429-A NIOBIUM OR TANTALUM COMPLEXES; OXYGEN-MOISTURE-FREE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199160-A1 STAT3 DIMERIZATION INHIBITORS STAT3, JAK2, STAT1 ALDH1A1 3098/4885SMN1; SMN2 3561/4885MAPT 3334/4885
US-20030119816-A1 Flavone derivatives, preparation method and use as medicines REN, CYP2F1, CYP3A43 ALDH1A1 1230/4885SMN1; SMN2 3046/4885MAPT 3647/4885
US-10954258-B2 STAT3 dimerization inhibitors STAT3, JAK2, STAT1 ALDH1A1 3098/4885SMN1; SMN2 3561/4885MAPT 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.